Silexion Therapeutics Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: Nov 25, 2025 · CIK: 2022416
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (SLXN) filed an 8-K on 11/25/25, reporting financials and exhibits.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on November 25, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, incorporated in the Cayman Islands, is based in Ramat-Gan, Israel, and operates in the biological products sector. Its principal executive offices are located at 12 Abba Hillel Road.
Why It Matters
This 8-K filing indicates routine corporate reporting, including financial statements and exhibits, for Silexion Therapeutics Corp. It confirms their operational status and regulatory compliance as of November 25, 2025.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for corporate reporting and does not appear to contain any significant new risks or material events.
Key Numbers
- 001-42253 — SEC File Number (Identifies the company's filing with the SEC.)
- 251515515 — Film Number (Internal SEC processing number.)
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- November 25, 2025 (date) — Date of report
- Cayman Islands (jurisdiction) — State of incorporation
- Ramat-Gan, Israel (location) — Address of principal executive offices
- 12 Abba Hillel Road (address) — Principal executive offices street
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report under Regulation FD and to include financial statements and exhibits as of November 25, 2025.
What was Silexion Therapeutics Corp.'s former name?
Silexion Therapeutics Corp.'s former name was Biomotion Sciences, with a date of name change on May 6, 2024.
Where are Silexion Therapeutics Corp.'s principal executive offices located?
Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.
In which jurisdiction was Silexion Therapeutics Corp. incorporated?
Silexion Therapeutics Corp. was incorporated in the Cayman Islands.
What is Silexion Therapeutics Corp.'s Standard Industrial Classification (SIC) code?
Silexion Therapeutics Corp.'s SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-11-25 09:25:39
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2534066.htm (8-K) — 49KB
- exhibit_99-1.htm (EX-99.1) — 12KB
- image0.jpg (GRAPHIC) — 15KB
- 0001178913-25-003949.txt ( ) — 256KB
- slxn-20251125.xsd (EX-101.SCH) — 5KB
- slxn-20251125_def.xml (EX-101.DEF) — 18KB
- slxn-20251125_lab.xml (EX-101.LAB) — 27KB
- slxn-20251125_pre.xml (EX-101.PRE) — 20KB
- zk2534066_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 25, 2025, Silexion Therapeutics Corp issued a press release entitled "Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer ". A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated November 25, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: November 25, 2025 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer